Cargando…

Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy

BACKGROUND: X-linked adrenoleukodystrophy (X-ALD) is highly variable, ranging from slowly progressive adrenomyeloneuropathy to severe brain demyelination and inflammation (cerebral ALD, CALD) affecting males with childhood peak onset. Risk models integrating blood-based biomarkers to indicate CALD o...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinhofer, Isabelle, Rommer, Paulus, Gleiss, Andreas, Ponleitner, Markus, Zierfuss, Bettina, Waidhofer-Söllner, Petra, Fourcade, Stéphane, Grabmeier-Pfistershammer, Katharina, Reinert, Marie-Christine, Göpfert, Jens, Heine, Anne, Yska, Hemmo A.F., Casasnovas, Carlos, Cantarín, Verónica, Bergner, Caroline G., Mallack, Eric, Forss-Petter, Sonja, Aubourg, Patrick, Bley, Annette, Engelen, Marc, Eichler, Florian, Lund, Troy C., Pujol, Aurora, Köhler, Wolfgang, Kühl, Jörn-Sven, Berger, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497986/
https://www.ncbi.nlm.nih.gov/pubmed/37683329
http://dx.doi.org/10.1016/j.ebiom.2023.104781
_version_ 1785105423320219648
author Weinhofer, Isabelle
Rommer, Paulus
Gleiss, Andreas
Ponleitner, Markus
Zierfuss, Bettina
Waidhofer-Söllner, Petra
Fourcade, Stéphane
Grabmeier-Pfistershammer, Katharina
Reinert, Marie-Christine
Göpfert, Jens
Heine, Anne
Yska, Hemmo A.F.
Casasnovas, Carlos
Cantarín, Verónica
Bergner, Caroline G.
Mallack, Eric
Forss-Petter, Sonja
Aubourg, Patrick
Bley, Annette
Engelen, Marc
Eichler, Florian
Lund, Troy C.
Pujol, Aurora
Köhler, Wolfgang
Kühl, Jörn-Sven
Berger, Johannes
author_facet Weinhofer, Isabelle
Rommer, Paulus
Gleiss, Andreas
Ponleitner, Markus
Zierfuss, Bettina
Waidhofer-Söllner, Petra
Fourcade, Stéphane
Grabmeier-Pfistershammer, Katharina
Reinert, Marie-Christine
Göpfert, Jens
Heine, Anne
Yska, Hemmo A.F.
Casasnovas, Carlos
Cantarín, Verónica
Bergner, Caroline G.
Mallack, Eric
Forss-Petter, Sonja
Aubourg, Patrick
Bley, Annette
Engelen, Marc
Eichler, Florian
Lund, Troy C.
Pujol, Aurora
Köhler, Wolfgang
Kühl, Jörn-Sven
Berger, Johannes
author_sort Weinhofer, Isabelle
collection PubMed
description BACKGROUND: X-linked adrenoleukodystrophy (X-ALD) is highly variable, ranging from slowly progressive adrenomyeloneuropathy to severe brain demyelination and inflammation (cerebral ALD, CALD) affecting males with childhood peak onset. Risk models integrating blood-based biomarkers to indicate CALD onset, enabling timely interventions, are lacking. Therefore, we evaluated the prognostic value of blood biomarkers in addition to current neuroimaging predictors for early detection of CALD. METHODS: We measured blood biomarkers in a retrospective, male CALD risk-assessment cohort consisting of 134 X-ALD patients and 66 controls and in a phenotype-blinded validation set (25 X-ALD boys, 4–13 years) using Simoa®and Luminex® technologies. FINDINGS: Among 25 biomarkers indicating axonal damage, astrocye/microglia activation, or immune-cell recruitment, neurofilament light chain (NfL) had the highest prognostic value for early indication of childhood/adolescent CALD. A plasma NfL cut-off level of 8.33 pg/mL, determined in the assessment cohort, correctly discriminated CALD with an accuracy of 96% [95% CI: 80–100] in the validation group. Multivariable logistic regression models revealed that combining NfL with GFAP or cytokines/chemokines (IL-15, IL-12p40, CXCL8, CCL11, CCL22, and IL-4) that were significantly elevated in CALD vs healthy controls had no additional benefit for detecting neuroinflammation. Some cytokines/chemokines were elevated only in childhood/adolescent CALD and already upregulated in asymptomatic X-ALD children (IL-15, IL-12p40, and CCL7). In adults, NfL levels distinguished CALD but were lower than in childhood/adolescent CALD patients with similar (MRI) lesion severity. Blood GFAP did not differentiate CALD from non-inflammatory X-ALD. INTERPRETATION: Biomarker-based risk prediction with a plasma NfL cut-off value of 8.33 pg/mL, determined by ROC analysis, indicates CALD onset with high sensitivity and specificity in childhood X-ALD patients. A specific pro-inflammatory cytokine/chemokine profile in asymptomatic X-ALD boys may indicate a primed, immanent inflammatory state aligning with peak onset of CALD. Age-related differences in biomarker levels in adult vs childhood CALD patients warrants caution in predicting onset and progression of CALD in adults. Further evaluations are needed to assess clinical utility of the NfL cut-off for risk prognosis of CALD onset. FUNDING: 10.13039/501100002428Austrian Science Fund, 10.13039/501100008731European Leukodystrophy Association.
format Online
Article
Text
id pubmed-10497986
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104979862023-09-14 Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy Weinhofer, Isabelle Rommer, Paulus Gleiss, Andreas Ponleitner, Markus Zierfuss, Bettina Waidhofer-Söllner, Petra Fourcade, Stéphane Grabmeier-Pfistershammer, Katharina Reinert, Marie-Christine Göpfert, Jens Heine, Anne Yska, Hemmo A.F. Casasnovas, Carlos Cantarín, Verónica Bergner, Caroline G. Mallack, Eric Forss-Petter, Sonja Aubourg, Patrick Bley, Annette Engelen, Marc Eichler, Florian Lund, Troy C. Pujol, Aurora Köhler, Wolfgang Kühl, Jörn-Sven Berger, Johannes eBioMedicine Articles BACKGROUND: X-linked adrenoleukodystrophy (X-ALD) is highly variable, ranging from slowly progressive adrenomyeloneuropathy to severe brain demyelination and inflammation (cerebral ALD, CALD) affecting males with childhood peak onset. Risk models integrating blood-based biomarkers to indicate CALD onset, enabling timely interventions, are lacking. Therefore, we evaluated the prognostic value of blood biomarkers in addition to current neuroimaging predictors for early detection of CALD. METHODS: We measured blood biomarkers in a retrospective, male CALD risk-assessment cohort consisting of 134 X-ALD patients and 66 controls and in a phenotype-blinded validation set (25 X-ALD boys, 4–13 years) using Simoa®and Luminex® technologies. FINDINGS: Among 25 biomarkers indicating axonal damage, astrocye/microglia activation, or immune-cell recruitment, neurofilament light chain (NfL) had the highest prognostic value for early indication of childhood/adolescent CALD. A plasma NfL cut-off level of 8.33 pg/mL, determined in the assessment cohort, correctly discriminated CALD with an accuracy of 96% [95% CI: 80–100] in the validation group. Multivariable logistic regression models revealed that combining NfL with GFAP or cytokines/chemokines (IL-15, IL-12p40, CXCL8, CCL11, CCL22, and IL-4) that were significantly elevated in CALD vs healthy controls had no additional benefit for detecting neuroinflammation. Some cytokines/chemokines were elevated only in childhood/adolescent CALD and already upregulated in asymptomatic X-ALD children (IL-15, IL-12p40, and CCL7). In adults, NfL levels distinguished CALD but were lower than in childhood/adolescent CALD patients with similar (MRI) lesion severity. Blood GFAP did not differentiate CALD from non-inflammatory X-ALD. INTERPRETATION: Biomarker-based risk prediction with a plasma NfL cut-off value of 8.33 pg/mL, determined by ROC analysis, indicates CALD onset with high sensitivity and specificity in childhood X-ALD patients. A specific pro-inflammatory cytokine/chemokine profile in asymptomatic X-ALD boys may indicate a primed, immanent inflammatory state aligning with peak onset of CALD. Age-related differences in biomarker levels in adult vs childhood CALD patients warrants caution in predicting onset and progression of CALD in adults. Further evaluations are needed to assess clinical utility of the NfL cut-off for risk prognosis of CALD onset. FUNDING: 10.13039/501100002428Austrian Science Fund, 10.13039/501100008731European Leukodystrophy Association. Elsevier 2023-09-07 /pmc/articles/PMC10497986/ /pubmed/37683329 http://dx.doi.org/10.1016/j.ebiom.2023.104781 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Articles
Weinhofer, Isabelle
Rommer, Paulus
Gleiss, Andreas
Ponleitner, Markus
Zierfuss, Bettina
Waidhofer-Söllner, Petra
Fourcade, Stéphane
Grabmeier-Pfistershammer, Katharina
Reinert, Marie-Christine
Göpfert, Jens
Heine, Anne
Yska, Hemmo A.F.
Casasnovas, Carlos
Cantarín, Verónica
Bergner, Caroline G.
Mallack, Eric
Forss-Petter, Sonja
Aubourg, Patrick
Bley, Annette
Engelen, Marc
Eichler, Florian
Lund, Troy C.
Pujol, Aurora
Köhler, Wolfgang
Kühl, Jörn-Sven
Berger, Johannes
Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy
title Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy
title_full Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy
title_fullStr Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy
title_full_unstemmed Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy
title_short Biomarker-based risk prediction for the onset of neuroinflammation in X-linked adrenoleukodystrophy
title_sort biomarker-based risk prediction for the onset of neuroinflammation in x-linked adrenoleukodystrophy
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497986/
https://www.ncbi.nlm.nih.gov/pubmed/37683329
http://dx.doi.org/10.1016/j.ebiom.2023.104781
work_keys_str_mv AT weinhoferisabelle biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT rommerpaulus biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT gleissandreas biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT ponleitnermarkus biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT zierfussbettina biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT waidhofersollnerpetra biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT fourcadestephane biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT grabmeierpfistershammerkatharina biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT reinertmariechristine biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT gopfertjens biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT heineanne biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT yskahemmoaf biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT casasnovascarlos biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT cantarinveronica biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT bergnercarolineg biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT mallackeric biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT forsspettersonja biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT aubourgpatrick biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT bleyannette biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT engelenmarc biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT eichlerflorian biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT lundtroyc biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT pujolaurora biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT kohlerwolfgang biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT kuhljornsven biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy
AT bergerjohannes biomarkerbasedriskpredictionfortheonsetofneuroinflammationinxlinkedadrenoleukodystrophy